Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3

Core Viewpoint - Tarsus Pharmaceuticals, Inc. (TARS) is highlighted as a Buy due to the rapid commercialization of its product Xdemvy following FDA approval in July 2023, leading to a significant appreciation in stock value since the recommendation [1]. Company Background - Tarsus Pharmaceuticals was founded by an individual with a Ph.D. in organic synthesis from Stanford University and has experience working for major pharmaceutical companies and biotech startups [1]. Stock Performance - The stock of Tarsus Pharmaceuticals has appreciated significantly since the recommendation was made in March 2023, indicating positive market reception and investor confidence in the company's future prospects [1].